

1645

OCT 0 3 2001

ttorney Docket No. UCSF-018/02US

TECH ULNICH 1600/2900

**PATENT** 

the by certify that this correspondence is being deposited with the United States Postal Service with the Un

By: Jeff Hibbett

## IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of Richard I. WEINER, et al.

Serial No.:

09/819,094

Examiner:

Not Yet Assigned

Confirmation No.: 6968

Art Unit:

1645

Filed:

March 27, 2001

For:

NOVEL ANTIANGIOGENIC PEPTIDE

**AGENTS** 

AND THEIR

THERAPEUTIC AND DIAGNOSTIC USE

Commissioner for Patents Washington, D.C. 20231

## INFORMATION DISCLOSURE STATEMENT TRANSMITTAL

Enclosed is an Information Disclosure Statement and accompanying Form PTO/SB/08 for the above-identified patent application.

paper is being submitted in duplicate.

[X]	In accordance with 37 C.F.R. §1.97(b), no additional fee for submission of the IDS is required.				
[]	In accordance with 37 C.F.R. §1.97(c), also enclosed is:				
	[] the fee of \$180.00 as set forth in 37 C.F.R. §1.17(p); or				
	[] a statement as specified in 37 C.F.R. §1.97(e).				
[]	In accordance with 37 C.F.R. §1.97(d), a statement as specified in 37 C.F.R. § 1.97(e) and the fee of \$180.00 as set forth in 37 C.F.R. §1.17(p) are also enclosed.				
[-]	Check No in the amount of \$ for the total fee is attached.				
[]	Please charge \$ to Deposit Account No. 03-3117 for the total fee. This				

The Commissioner is hereby authorized to charge any appropriate fees under 37 C.F.R. §§1.16, 1.17, and 1.21 that may be required by this paper, and to credit any overpayment, to Deposit Account No. 03-3117.

Dated. Sept 6, 200

Cooley Godward LLP ATTN: Patent Group Five Palo Alto Square 3000 El Camino Real Palo Alto, CA 94306-2155

Tel: (650) 843-5000 Fax: (650) 857-0663 Respectfully submitted, COOLEY GODWARD LLP

By:

Marcella Lillis, Ph.D. Reg. No. 36,583

I hereby certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as first class mail in an envelope addressed to the Commissioner for Patents, washington, D.C. 20231 on September 6, 2001.

y: Jeff Ac

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re application of Richard I. WEINER, et al.

Serial No.:

09/819,094

Examiner:

Not Yet Assigned

Confirmation No.: 6968

Art Unit:

1645

Filed:

DCT 0 1 2001

March 27, 2001

For:

NOVEL ANTIANGIOGENIC PEPTIDE

**AGENTS** 

AND

THEIR

THERAPEUTIC AND DIAGNOSTIC USE

Commissioner for Patents Washington, D.C. 20231

## INFORMATION DISCLOSURE STATEMENT UNDER 37 C.F.R. §1.97(b)

In accordance with the duty of disclosure set forth in 37 C.F.R. §1.56, Applicant(s) hereby submits the following information in conformance with 37 C.F.R. §§1.97 and 1.98.

- [X] Pursuant to 37 C.F.R. §1.98, copies of P3, D6, D15, D17, D24 and D29 cited in the attached Form PTO/SB/08 are enclosed.
- [X] No copies of the publications P1-P2, D1-D5, D7-D14, D16, D18-D23, D25-D28 and D30-D31 listed on the attached Form PTO/SB/08 are being provided pursuant to 37 C.F.R. §1.98(d) because the publications were previously cited by or submitted to the Office in prior Application Serial No. 09/076,675 to which the above-identified application claims priority under 35 U.S.C. §120.
- [] Publication(s) \_\_ listed on the attached Form PTO/SB/08 were cited in a foreign search or examination report corresponding to \_\_ application serial no. \_\_ and mailed on \_\_.

[]	Enclosed is a copy of a non-English publication(s) Pursuant to §609 of the M.P.E.P., Applicant submits the attached foreign search or examination report, which cites such non-English language publication(s).					
0	Enclosed is a copy of a non-English publication(s) English language publication (copy enclosed) claims priority from this non-English publication.					
[]	Enclosed is an explanation of non-English publication(s) for which an English translation is not available.					
[]	Enclosed is an English translation of non-English publication(s)cited in the attached Form PTO/SB/08.					
[]	Enclosed is a copy of pending patent Application Serial No					
This Information Disclosure Statement is filed within any one of the following time periods:						
	[] within three months from the filing date of this national application other than a CPA under 37 C.F.R. § 1.53(d);					
	[] within three months from the date of entry of the national stage as set forth in 37 C.F.R. §1.491 in this international application;					
	[X] before the mailing date of a first office action on the merits; or					
	[] before the mailing of a first office action after the filing of a request for continued examination under 37 C.F.R. § 1.114.					
It is respectfully requested that the Examiner consider the above-noted						
information and return an initialed copy of the attached Form PTO/SB/08 to the						
undersigned.						
Dated: Sept 6, 2001 Respectfully submitted, COOLEY GODWARD LLP						
Cooley Godward LLP						
ATTN: Patent Group Five Palo Alto Square						
3000 El Camino Real Palo Alto, CA 94306-2155						
Ry: // VIII/ / // // // //						
Tel: (650) 843-5000  Fax: (650) 857-0663  Marcella Lillis, Ph.D.  Part No. 26, 582						
Reg. No. 36,583						